Dana-Farber Cancer Institute shared a post on LinkedIn:

“Edward Chouchani, PhD, of Cancer Biology and associate professor of cell biology at Harvard Medical School, is one of five early-career investigator recipients of the 2024 Emerging Leader Awards from The Mark Foundation. Chouchani will receive $750,000 over the course of three years for his project, ‘Defining the protein regulome targeted by lactate and other central carbon oncometabolites.’ The award supports high-impact, high-risk projects that aim to address urgent needs in cancer research.

‘Being recognized with The Mark Foundation Emerging Leader Award is an immense honor,’ expresses Chouchani. ‘This award reinforces our commitment to understanding fundamental metabolic mechanisms at the heart of cancer biology. I’m very grateful.’

For a century, researchers believed that lactate, a metabolic hallmark of aggressive cancers, accumulates as an inert metabolic byproduct of cell growth and division. Recent discoveries in Chouchani’s lab overturned this idea and proposed a novel biochemical mechanism that positions lactate as a critical metabolic signal in cancer cells. His project seeks to understand how accumulated lactate can directly control a tumor’s genetic identity and how it grows, functions, and metastasizes through this new paradigm.

The Mark Foundation for Cancer Research, a charitable organization based in New York City, partners with scientists around the world to accelerate research to transform the prevention, diagnosis, and treatment of cancer.”

Source: Dana-Farber Cancer Institute/LinkedIn

Dana-Farber Cancer Institute, located in Boston, Massachusetts, is a leading institution for cancer treatment and research. It was founded by Sidney Farber on 1947. Currently, the Institute has over 5,000 staff, faculty, and clinicians on board. They manage in excess of 640,000 outpatient visits each year, oversee more than 1,000 hospital discharges annually, and are actively involved in over 1,100 ongoing clinical trials.

As of 2023, Dana-Farber is ranked as the #4 cancer hospital globally. Dana-Farber’s research contributions include the development of Gleevec, a highly successful treatment for chronic myeloid leukemia.